18 terminated. 18 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 18 | Terminated 18 |
| Phase 2 | 2 | Terminated 2 |
Follow Motor Neuron Disease: new trials by email Literature Review of Motor Neuron Disease trials Research Report on Motor Neuron Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial Abacavir 600mg, Lamivudine 300mg and Dolutegravir 50mg (Triumeq) - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Macquarie University, Australia | 12 | 2024-11-15 | 2025-06-08 |
| Continuation Study for Latozinemab Latozinemab - Neurodegenerative Diseases | Phase 3 | Terminated | Alector Inc. | 17 | 2023-12-08 | 2026-01-21 |
| Study to Investigate the Long-term Safety of FAB122 in Patients With Amyotrophic Lateral Sclerosis FAB122 - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Ferrer Internacional S.A. | 201 | 2023-03-06 | 2025-03-04 |
| A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031) Reldesemtiv - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Cytokinetics | 71 | 2022-08-04 | 2024-08-13 |
| Triumeq in Amyotrophic Lateral Sclerosis Dolutegravir, Abacavir and Lamivudine, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Macquarie University, Australia | 419 | 2022-02-24 | 2025-07-11 |
| Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer Enobosarm, Exemestane - Metastatic Breast Cancer | Phase 3 | Terminated | Veru Inc. | 52 | 2021-10-12 | 2024-01-26 |
| A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) Reldesemtiv, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Cytokinetics | 489 | 2021-08-16 | 2024-12-05 |
| Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS) Lithium Carbonate 400 MG - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Stichting TRICALS Foundation | 88 | 2021-08-09 | 2026-05-13 |
| An Efficacy and Safety Study of Ravulizumab in ALS Participants Placebo, Ravulizumab - Amyotrophic Lateral Sclerosis, ALS | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 382 | 2020-03-30 | 2023-01-10 |
| Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial Arimoclomol - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | ZevraDenmark | 120 | 2019-09-19 | 2023-08-24 |
| Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension Levosimendan - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Orion Corporation, Orion Pharma | 227 | 2019-06-26 | 2023-03-09 |
| Study of Acthar® Gel (Acthar) for Amyotrophic Lateral Sclerosis (ALS) Acthar, Placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Terminated | Mallinckrodt | 143 | 2017-06-22 | 2020-10-14 |
| A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy nusinersen, Sham procedure - Spinal Muscular Atrophy | Phase 3 | Terminated | Biogen | 122 | 2014-08-19 | 2021-02-17 |
| Early Stage Amyotrophic Lateral Sclerosis Phrenic Stimulation phenique nerve stimulation NeurX™ (Synapse Biomedical), sham phrenic nerve stimulation - Amyotrophic Lateral Sclerosis, Respiratory Insufficiency | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 74 | 2012-09-01 | 2015-12-22 |
| Phase 3 Extension Study of Dexpramipexole in ALS Dexpramipexole - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Knopp Biosciences | 616 | 2012-06-01 | 2022-05-03 |
| Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) KetoCal - Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Johns Hopkins University | 1 | 2009-11-01 | 2015-04-01 |
| Evaluation of a Mechanical Device During Acute Respiratory Failure in Patients With Neuromuscular Disorders mechanical insufflation - exsufflation, Standard respiratory physiotherapy - Duchenne Muscular Dystrophy, Amyotrophic Lateral Sclerosis | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 14 | 2009-06-01 | 2015-05-28 |
| Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) Lithium Carbonate, Riluzole, placebo - Amyotrophic Lateral Sclerosis | Phase 2 / Phase 3 | Terminated | Massachusetts General Hospital | 84 | 2009-01-01 | 2011-04-19 |
Amyotrophic Lateral Sclerosis (16) · Breast Neoplasms (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Frontotemporal Dementia (1) · Muscular Atrophy, Spinal (1) · Muscular Dystrophy, Duchenne (1) · Myotonia Congenita (1) · Nerve Degeneration (1) · Neurodegenerative Diseases (1) · Neuromuscular Diseases (1) · Respiratory Insufficiency (1)
Central Nervous System Diseases (18) · Nervous System Diseases (18) · Spinal Cord Diseases (18) · Neurodegenerative Diseases (17) · Neuromuscular Diseases (17) · Metabolic Diseases (16) · Nutritional and Metabolic Diseases (16) · Proteostasis Deficiencies (16) · TDP-43 Proteinopathies (16) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Genetic Diseases, X-Linked (2) · Heredodegenerative Disorders, Nervous System (2) · Brain Diseases (1)
Lithium Carbonate (2) · abacavir, dolutegravir, and lamivudine drug combination (2) · reldesemtiv (2) · Adrenocorticotropic Hormone (1) · Dexpramipexole (1) · Lamivudine (1) · Riluzole (1) · Simendan (1) · abacavir (1) · arimoclomol (1) · dolutegravir (1) · exemestane (1) · nusinersen (1) · ostarine (1) · ravulizumab (1)
Assistance Publique - Hôpitaux de Paris (2) · Cytokinetics (2) · Macquarie University, Australia (2) · Alector Inc. (1) · Alexion Pharmaceuticals, Inc. (1) · Biogen (1) · Ferrer Internacional S.A. (1) · Johns Hopkins University (1) · Knopp Biosciences (1) · Mallinckrodt (1) · Massachusetts General Hospital (1) · Orion Corporation, Orion Pharma (1) · Stichting TRICALS Foundation (1) · Veru Inc. (1) · ZevraDenmark (1)
United States (12) · Spain (11) · Canada (10) · Sweden (10) · Australia (9) · Belgium (9) · France (9) · Netherlands (9) · United Kingdom (9) · Germany (7) · Italy (7) · Ireland (6) · Poland (4) · Denmark (2) · Japan (2)
Gonzalez-Bermejo Jesus, Md, PhD (1) · Jinsy Andrews, MD (1) · Julian Gold, MD, FFPHM (1) · Leonard Van den Berg, MD (1) · Lorne Zinman, MD, MSc, FRCPC (1) · Merit Cudkowicz, MD, MSc (1) · Michael Benatar, MD PhD (1) · Michael Bozik, MD (1)
PMID 20363190, PMID 27751553, PMID 27939059, PMID 29091570, PMID 30523161, PMID 30879249, PMID 31420846, PMID 34536404, PMID 37254449, PMID 37695623, PMID 37794802, PMID 38705943, PMID 40126464, PMID 40503807, PMID 40576049, PMID 41121745, PMID 41553108
2019 (1), 2023 (1), U01NS049640 (1)